A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

BACKGROUND: The mesenchymal-epithelial transition factor (MET) receptor is dysregulated in hepatocellular carcinoma (HCC), and tivantinib (ARQ 197) is an oral, selective, MET inhibitor. METHODS: This Phase-1b study assessed tivantinib safety as primary objective in patients with previously treated H...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Santoro, A, Simonelli, M, Rodriguez-Lope, C, Zucali, P, Camacho, L H, Granito, A, Senzer, N, Rimassa, L, Abbadessa, G, Schwartz, B, Lamar, M, Savage, R E, Bruix, J
Format:	Artigo
Sprog:	Inglês
Udgivet:	Nature Publishing Group 2013
Fag:	Clinical Study
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3553536/ https://ncbi.nlm.nih.gov/pubmed/23287988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.556
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

Lignende værker